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Abstract
Background: A real-time clinical decision support system (RTCDSS) with interactive diagrams enables clinicians to
instantly and efficiently track patients’ clinical records (PCRs) and improve their quality of clinical care. We propose
a RTCDSS to process online clinical informatics from multiple databases for clinical decision making in the
treatment of prostate cancer based on Web Model-View-Controller (MVC) architecture, by which the system can
easily be adapted to different diseases and applications.
Methods: We designed a framework upon the Web MVC-based architecture in which the reusable and extractable
models can be conveniently adapted to other hospital information systems and which allows for efficient database
integration. Then, we determined the clinical variables of the prostate cancer treatment based on participating
clinicians’ opinions and developed a computational model to determine the pretreatment parameters.
Furthermore, the components of the RTCDSS integrated PCRs and decision factors for real-time analysis to provide
evidence-based diagrams upon the clinician-oriented interface for visualization of treatment guidance and health
risk assessment.
Results: The resulting system can improve quality of clinical treatment by allowing clinicians to concurrently
analyze and evaluate the clinical markers of prostate cancer patients with instantaneous clinical data and evidence-
based diagrams which can automatically identify pretreatment parameters. Moreover, the proposed RTCDSS can
aid interactions between patients and clinicians.
Conclusions: Our proposed framework supports online clinical informatics, evaluates treatment risks, offers
interactive guidance, and provides real-time reference for decision making in the treatment of prostate cancer. The
developed clinician-oriented interface can assist clinicians in conveniently presenting evidence-based information
to patients and can be readily adapted to an existing hospital information system and be easily applied in other
chronic diseases.
Background
In clinical practice, clinicians encounter a number of
common problems when it comes to improving the
quality of clinical treatments as follows: (1) clinicians
may take several hours, or even a couple of days, to
review patients’ clinical records (PCRs) but only have a
few minutes to explain their opinions to patients based
on their records; (2) patients typically find it difficult to
understand their condition since clinicians may only be
able to explain the disease adequately using written
descriptions; (3) although the traditional clinical decision
support system (CDSS) is computerized, in many clinics
it may not have online capability; (4) many commercial
utilities provide computational tools but real-time analy-
sis is not available unless the required modules are reu-
sable or extractable. Therefore, many clinicians are in
need of an expandable CDSS with an interactive dia-
grammed interface which can be used as an effective
tool to efficiently evaluate instant PCRs and to make
clinical decisions.
The research indicates that publicly released clinical
evidence data seems to improve patient care quality at
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the hospital level [1]. Hence, a computerized clinical
data analysis and information technology (IT)-based
decision support system may be of value in decreasing
workflow and data collection errors in order to improve
communication with patients and enhance patient
safety. Many studies have demonstrated that the conse-
quences of errors in medical care were reduced by the
use of computer-based CDSS in the provision of care in
terms of clinician performance and patient outcome.
Moreover, the results of several studies have shown
improvements for drug dosing, preventive care, and
other aspects of medical care with the use of computer-
based CDSS, but their use in diagnosis has, to date,
been less convincing [2-4]. Thus, a clinician-oriented
interface with real-time analysis may be the key to
improving accuracy and efficiency of the CDSS to meet
hospitals’ needs. Numerous CDSSs have been developed
over the years for a variety of clinical approaches, such
as the Web-based consultation library with evidence-
based clinical literature, which can be searched and
accessed remotely [5], the clinical decision model for
integration with other clinical systems [6], and the initial
framework of electronic patient self-assessment for
healthcare awareness in cancer survivorship progress
[7]. A platform with a flexible framework design which
is capable of satisfying clinical requirements for diverse
disease treatments is therefore needed.
Thus, we proposed a real-time clinical decision sup-
port system (RTCDSS) upon a reusable framework that
was built with the extractable process models which
support online clinical informatics. In addition, we
designed a clinician-oriented interface to help the clini-
cian process instantaneous clinical data for decision
making. The system was initially applied for use in pros-
tate cancer treatment as a pilot study. It has been well
established in the literature that prostate-specific antigen
(PSA) level, Gleason grade, and clinical TNM (tumor/
nodes/metastases) stage are essential for developing a
treatment strategy for prostrate cancer. Watchful wait-
ing, radiation therapy, and surgery are generally offered
to men whose cancer remains within the prostate;
whereas hormonal therapy and chemotherapy are often
reserved for those whose disease has spread beyond the
prostate. To facilitate these treatments, many studies
have suggested analytical tools to assist clinicians in esti-
mating the relative pretreatment parameters and for
tracking the proper diagnostic guidelines on visualized
interfaces [8-14]. From clinical data tracking to real-
time decision making tools, the flexible Web-based
CDSS with online evidence-based medicine progress is a
growing trend in advanced clinical care.
In this study, we developed a RTCDSS with novel Web
technologies to integrate PCRs and patient-report out-
comes (PROs) in order to generate visualized diagrams
and interactive guidelines. The framework can be readily
adapted for use by many hospital information systems
(HISs). Herein, reusable computation models are intro-
duced in subsequent sections. The major schema of the
system is addressed in the methods section and the
method of integrating the necessary components is
described in the development section. In the results and
discussions sections, the processes by which the system
obtains the online pretreatment parameters and imple-
ments them for real-time decisions at clinic visits are
described.
Methods
The scope of the proposed system include: (a) to allow
for flexible adaption of the functionality for heteroge-
neous HISs through the Internet, (b) to instantly present
online PROs and PCRs for prostate cancer patients, and
(c) to provide a user-friendly clinician-oriented interface
for clinicians. We thus used the model-view-controller
(MVC) design pattern with Web services to create a
MVC-based architecture. The concept of this design
pattern was first made available by Gamma et al. [15]
who introduced 23 patterns associated with creational,
structural and behavioral models of software design to
process recurrent elements. The MVC essentially creates
a hybrid of three of them: the strategy, observer, and
composite patterns. It also divides system responsibil-
ities into three parts: the model, which maintains pro-
gram data and logic; the view, which provides a visual
presentation of the model; and the controller, which
processes user input and makes modifications to the
model. With this architecture, the framework allows for
reusable components to be applied in an expandable
system and reduces the development complexity of
Web-based applications. The framework of the proposed
RTCDSS includes affiliated models, views and control-
lers for clinical informatics and implements Web ser-
vices for online analytical process (OLAP).
OLAP upon MVC-based Architecture
The built-in elements within the framework should be
reusable and extractable to enable clinical analysis and
decision support for clinical cares which includes:
a) instantaneous disease evaluation, b) risk analysis, and
c) treatment guidance. For these tasks, we designed the
infrastructure of MVC-based architecture, shown in
Figure 1, so that it involves presentation, management,
analysis, and database tiers.
(i) Models
The models are categorized into four main groups: dis-
ease evaluation, risk analysis, treatment guidance, and
data processing models. They are denoted by hexagonal
blocks, in which the first three models are related to
clinical data computation while the last one represents
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the other IT modules. The disease evaluation model pri-
marily contains modules to retrieve clinical variables,
calculate pretreatment parameters, and evaluate PROs
and PCRs. The risk analysis model drives algorithms to
analyze clinical variables and parameters, identify risk
indicators and criteria, and so on. The guidance criteria
model enables the generation of evidence-based dia-
grams, online guidance and decision support. The rest
of the IT-related modules such as clinical data conver-
sion, database connection, and graphical display, are
included in the data processing model.
(ii) Views
The views denoted by the rectangles can implement the
clinician-oriented interface directly with the OLAP portal
and the evidence-based informatics for clinicians at the
presentation tier. Similarly, the view of management
interface support provides IT engineers with security
administration at the management tier. Meanwhile,
researchers can take care of all clinical data through the
analysis view at the analysis and database tiers. Based on
this design, these views are behind the major components
of each tier denoted in the ellipse blocks such as real-
time diagrams, interactive guidelines, privilege adminis-
tration, informatics management, data filtering and data
analysis tools.
(iii) Controllers
The controllers denoted by the rhombus support inter-
actions among the models and views within the infra-
structure. At the presentation tier, the controllers
process data flow transformation and data input valida-
tion when the clinicians begin online inquiries. At the
management tier, the privilege control and role identifi-
cation are required when the engineers are conducting
system maintenance. Meanwhile, the clinical data at the
back tiers of analysis and database are coordinated by
heterogeneous data transaction.
Based on this MVC-architecture, the online clinical
informatics can be achieved by the OLAP mechanism.
The OLAP is utilized as a decision support platform
since it supports efficient online functionalities with
computation algorithms upon the data warehouse [16].
For example, the clinician is a decision maker who
Figure 1 Infrastructure of the RTCDSS upon MVC-based architecture.
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represents the presentation tier which performs the
components of the interactive guideline and real-time
diagrams in the clinic. These components present online
clinical informatics with the views of “OLAP portal” and
“evidence-based informatics” by executing the computa-
tion models through the controllers of “data flow trans-
formation” and “role identification”. The rest of the
object relationships may be deduced by comparing with
the other tiers. Based upon this framework, all objects
are independent but enable reciprocal supports through
Web services. The proposed system was constructed by
using Java™ technology to provide a clinician-oriented
interface in a Web browser for real-time online decision
support.
Management of Distributed Database
The OLAP needs to process diverse clinical data within
a variety of systems, thus two types of data flows should
be considered: distributed database (DDB) management
and extensible markup language (XML) schema. The
DDB management coordinates the related PROs and
PCRs of prostate cancer data that are stored in various
systems. The architecture supports a virtual and centra-
lized database to aggregate data from multiple databases.
It provides transparent data transaction that allows users
to alternate between sets of data as if there is an auton-
omous database operating independently of levels of dis-
tribution or heterogeneity. Meanwhile, the transportable
XML documents contain a tree structure with hierarchi-
cal node elements that records data within the local ser-
ver. Thus, we can parse subsequent nodes from XML
files to retrieve the data. Some online data validations
only request simple criteria instead of frequent database
transaction. Hence, the XML schema is used for acces-
sing distributed light-weight data through Web services.
To enhance performance of data transaction, the
approach retains heavy-mass data necessary for routine
query within the database server, (e.g., clinical variables,
PROs and PCRs) and accesses lightweight data for
online analysis in the Web server, (e.g., decision support
criteria, treatment guidelines). This design takes load
balance into consideration which is an important system
performance factor when the data are spread across
multiple Web servers. By using XML schema, the data
for decision support are transformed into Web services
documents in the Web server. Meanwhile, masses of
clinical data are analyzed at the backend and provide
expert opinions for feedback to the data warehouse.
Therefore, complex data queries are not saved on the
Web server site but instead are left on the database ser-
vers. The data transaction can then be done smoothly
for efficient workflows on both the Web and database
servers.
Development
While developing the proposed system, we first consid-
ered the requirements of online clinical informatics for
prostate cancer treatments. We then discovered the fra-
mework of the RTCDSS to enable real-time decision
making with heterogeneous data computation. Partici-
pating clinicians suggested using clinical variables below
for long-term tracking and we applied statistical algo-
rithms to create computation models for analyzing the
pretreatment parameters and providing feedback of
expert opinions.
System Requirements for Decision Support
Prostate cancer is known to occur when genetic muta-
tions of the prostate take place which then causes cells
to begin multiplying out of control. Local invasion of
tumors can lead to urethral obstruction and even renal
failure while they spread to the bones and lymph nodes
[17]. Among urologic malignancies, prostate cancer has
greatly benefited from the discovery of a tumor marker
and disease staging. The combination of treatments and
serum PSA, particularly the initial PSA after a treat-
ment, is the most useful clinical information for detect-
ing, staging, and monitoring prostate cancer patients
when assessing the risk of prostate cancer [18-21]; Dis-
ease stage, based on the TNM system, which includes
the size of the tumor, the number of involved lymph
nodes, and the presence of any other metastases, indi-
cates how far the cancer has spread for defining prog-
nosis and selecting therapies. Herein, the clinical
variables were retrieved from heterogeneous databases
of a HIS through different networks via secure interfaces
adapted to the proposed system.
(i.) PSA Level
The presence of prostate diseases is the most important
factor affecting serum levels of PSA [22,23]. Many stu-
dies have made efforts to evaluate other thresholds to
maximize the positive biopsy rate of PSA-based screen-
ing [24-27]. The PSA-related parameters including PSA
density (PSAD), PSA velocity (PSAV) and PSA doubling
time (PSADT) are considered to improve diagnostic
accuracy of PSA.
A direct relationship between PSAD and the likeli-
hood of cancer has been documented [28], and higher
PSA densities may be found among groups of men with
positive biopsies compared with men with negative
biopsies [29]. PCRs can be filtered to rank high risk
patients who have relatively smaller prostate volumes
when a constant number of biopsies are obtained.
PSAV is the rate of change in serum PSA. A rate in
excess of 0.75 ng/mL per year is a significant indicator
of the presence of prostate cancer and some studies
have suggested increasing the cut point to more than
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2 ng/mL of PSA per year for prediction of prostate can-
cer [30,31]. We can estimate PSAV by applying linear
regression to PSA data. A linear equation for arbitrary
PSA (Pi) with respect to time (Ti) can then be formu-
lated. The estimator Pi at time Ti can be denoted by the
equation, Pi = initial PSA + PSAV * Ti. In practice, Ti
can be counted by days, months or years.
PSADT is denoted as the duration when the logarithm
of PSA doubles and has been evaluated in patients with
a rising PSA after local treatment with radiation therapy
[32]. In order to obtain the PSADT value, we can substi-
tute the regression equation of PSAV into the half-loga-
rithmic coordinate of ln(Pi) versus Ti, and a straight line
is obtained to calculate doubling PSA at doubling time
TD. Therefore, if two arbitrary PSAs (P1 and P2) are
measured at time T1 and T2, respectively, TD can be
estimated as ln(2*P1) is interpolated. Similarly, Ti can be
counted by days, months or years.
(ii.) TNM stage
The well-known TNM classification system generally
evaluates the size of the tumor (T) by four stages, the
extent of involved lymph nodes (N) by two stages, and
any metastasis (M) by two stages. In this study, version
6 of the TNM system published by the American Joint
Committee for Cancer (AJCC) and the International
Union against Cancer (UICC) in 2002 was used.
Evaluation Criteria of Expert Opinions
The significant pretreatment parameters described
below can be used to track prostate cancer patients peri-
odically and can be applied in the development of com-
putational models.
(i) Gleason grade and Partin table
The Gleason grading system is the most common
scheme for classifying the histological grading of pros-
tate cancer [33]. The predominant pattern that occupies
the largest area of the specimen is given a grade
between 1 and 5. This number is then added to the
grade assigned to the second most dominant pattern;
thus, a Gleason sum may be between 2 and 10. Partin
tables include primary tumor stage, serum PSA level,
and Gleason grade to determine the probability of hav-
ing a final pathologic stage based on logistic regression
analyses for all 3 variables combined [34,35]. In this
study, the system applied the Partin table used by the
National Comprehensive Cancer Network (NCCN).
(ii) Risk evaluation criteria
Risk evaluation criteria of prostate cancer is constructed
on the basis of large numbers of patients who have
undergone radical prostatectomy to aid in the precise
prediction of pathologic stage by using multiple clinical
parameters as accurate predictors of both cancer extent
and long-term outcomes after treatment of the primary
tumor [36]. We adopted the criteria suggested by
D’Amico et al. [37] to stratify patients into low-risk,
intermediate-risk, and high-risk disease, and to summar-
ize the failure status, as shown in Table 1. The criteria
define the risk factors for three levels of risk for three
conditions, i.e., (a) prostate-therapy PSA failure at
5 years, (b) PSA failure-free survival at 5 and (c)
10 years. In the table, for example, condition (a) pre-
sents three levels of risk less than 25%, between 25%
and 50%, and greater than 50% as the risk factors match
the criteria.
Based on the correlations of these pretreatment para-
meters with the true extent of disease, the RTCDSS can
integrate the clinical data and expert opinions available
for clinicians to determine the likelihood of disease pro-
gression and predict the pathologic stage.
Framework Integration with Clinical Data
In order to develop the RTCDSS efficiently, we consid-
ered an open source framework to integrate heteroge-
neous clinical data with required components above.
(i) Open Source Framework
The Spring™framework, which is well-known as a busi-
ness to business (B2B) open source framework in the IT
industry, was used to construct the platform for online
computation and distributed data management in a vari-
ety of HIS. The data flow follows throughout the stack
chart shown in Figure 2 to control the model objects
with the necessary procedure. Based on the chart, when
PCR data arrive at the object of the servlet container,
the framework begins the processes of assessing heavy-
mass and lightweight data and customizing the clinical
data logic until the object of Web context is fulfilled
with declared data. The Web services are then able to
manage declarative transaction and complete the object
of Internet data transformation for provision of the Web
application context. Then, on the next stack, one object
may drive the disease evaluation model with the MVC
pattern, and another object may take the risk analysis
model for inheriting a part of the clinical data. Thus,
they require the object of MVC integration to yield the
clinical informatics. Finally, the clinicians can present
evidence-based diagrams by interacting with the clinical
informatics. This dataflow allows these objects to con-
trol heavy and light clinical data access for balancing
loads.
(ii) Heterogeneous Data Integration
To incorporate pretreatment parameters with PCRs and
PROs for online analysis, we generated a clinical data
warehouse to support expert opinion feedback for deci-
sion making. Figure 3 presents a three-stage data pro-
gress flow from various source data to the data
warehouse. The source database for clinics would be
unified by the extract-transform-load (ETL) process of
software program to extract, transform, cleanse and load
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the transient data source with the stored procedure into
stage database. The pretreatment parameters were
further manipulated with transient data by analysis
applications to yield expert opinions and feedback to the
knowledge database behind the clinical data warehouse.
We used three primary controller modules, which are
dynamic views, stored procedures, and triggers, in the
database software to automatically perform data transac-
tions while integrating diverse data. The ETL process
conducts the data filtering function, as shown in Figure
1, while the data transformation application can be
adapted to employ analysis tools, such as the hazard
model, the survival model, or other statistical algorithms
by SAS™or Matlab™for feedback of expert opinions.
Using the developed components above, the proposed
framework can provide clinicians with the ability to
immediately assess pretreatment parameters in addition
to collating PCRs and PROs via online informatics,
which better enables them to inform and educate
patients during clinic visits.
Results
The proposed MCV-based RTCDSS contains 4 tiers, while
the groups of three models and two views within the pre-
sentation tier support clinicians’ decision making. The
three primary models are disease evaluation, guidance cri-
teria, and risk analysis, which are created by the feedback
of clinicians’ expert opinions. The diseases evaluation
model includes PCRs, such as PSA level, Gleason grade,
TNM stage, as well as PROs, such as real-time evaluation
for quality of life. We employed pretreatment parameters,
such as PSAV, PSAD, Partin tables, as the guidance cri-
teria for online clinical informatics of prostate cancer. The
risk analysis model was then used to compute the infor-
matics of disease evaluation and guidance criteria. The
results contain two views, which are the “OLAP portal”
and the “evidence-based informatics,” to provide clinician-
oriented interface with graphical diagrams that may aid
the interaction between clinicians and patients during dis-
cussion of treatment options. The proposed framework
was practiced in the urological cancer department of
China Medical University Hospital (CMUH) in Taichung,
Taiwan, by incorporating campus and hospital networks
using heterogeneous database management. The necessary
data resources were extracted and filtered from the pros-
tate cancer database of CMUH. Patients who received
treatments for prostate cancer were enrolled in the pilot
study which was approved by the institutional review
board (IRB). The design of the clinician-oriented interface
and its developed functions was evaluated with regard to
how well it helped clinicians interact with patients and
provide efficient clinical care.
A. Disease evaluation of the PSA level - Figure 4
shows the PSAV and PSADT values with PSA baseline
while the clinician enters the patient’s ID and selects an
arbitrary time interval. The real-time diagram shows the
disease information of the patient’s PSA level through-
out different treatments. It can be seen that the system
retrieved the patient’s data from PCRs and listed related
pretreatment parameters for an overview of the patient’s
disease history. The baseline of PSA was completely
plotted during different treatment cycles with significant
points (such as the initial PSA) of note. The clinicians
could evaluate both the PSAV and PSADT as two algo-
rithms were used by either using the average value of
listed PSAs or choosing two specific PSA markers.
Table 1 Risk Evaluations for Prostate Cancer
Risk group Risk factors Risk (a, b, c)%
Low T1c or T2a and PSA <= 10 ng/ml and Gleason score <= 6 (< 25, 85, 83)
Intermediate T2b or Gleason score = 7 or PSA > 10 and <= 20 ng/ml (25-50, 60, 46)
High T2c or PSA > 20 ng/ml or Gleason score >= 8 (> 50, 30, 29)
a. Post-therapy PSA failure at 5 yrs; b. PSA failure-free survival at 5 yrs;







Accessing Heavy-mass & Light-weight Data
Customizing Clinical Data Logic
Managing Declarative Transaction
Providing Web Application Context
Interacting Clinical Informatics
Figure 2 Clinical data flow throughout the integration
framework.
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B. Risk analysis with Partin tables - Using the Partin
tables module in the system, the clinician can easily find
and input pretreatment parameters such as PSA, Gleason
score, and a clinical stage to determine the risk percentage
shown in Figure 5. In the example, the clinician entered
the risk factors of the selected patient which were T1c,
32.4, and 5-6 for TNM stage, PSA value and Gleason
score, respectively. The system then estimated the recur-
rent risk percentage and classified patient into the high
risk group immediately while the pathological stage was
displayed with the Gleason score on a new web page of
the NCCN Partin table for reference. The risk evaluation
in Table 1 also represents the feedback of expert opinions
that may be adjusted by advance statistics.
C. Interactive treatment guidance - Figure 6 illustrates
the guideline flowchart by query pretreatment parameters
from PCRs and proposes the treatment phase based on
the criteria for decision making. According to the pre-
sented example, PSA was 82.35 ng/ml, the clinical stage
was T2cN0M0, Gleason Score was 4+3, life expectancy
was 15 years, and lymph node involvement was 38%, with
asymptomatic therapy. The pink region instantaneously
highlighted the therapeutic steps for reference while the
pathological information of the selected patient was
entered. By providing a comparison with the non-high-
lighted steps on the overview of guideline flow, the flow-
chart allows the clinicians to identify the current stage and
see what the next step is.
Discussions
Due to restrictions related to hospital management and
security policy, the system could not be used by all
Figure 3 The three-stage integration of clinical data in the RTCDSS.
Figure 4 A screen shot of interactive guidance that the clinicians can use to select the historical PSA data online to aid decision
making.
Lin et al. BMC Medical Informatics and Decision Making 2011, 11:16
http://www.biomedcentral.com/1472-6947/11/16
Page 7 of 11
clinical care staffs or be used beyond the hospital net-
work at all times. On this phase, we therefore focused
on the core system development and initial clinical
applications. Prior to this study, the participating clini-
cians would typically study patients’ data for several
hours before explaining the disease conditions to their
patients. During the study period, the clinicians were
able to use real-time online diagrams to help them
make clinical decisions and evaluate treatment effective-
ness. The biggest benefits of the system would likely be
enhanced clinical care for patients, better identification
of optimal treatment options, and increased efficiency in
clinics. The main advantages of the developed system
are described in more detail below.
A. Online informatics for clinicians
The greatest advantage conferred by this system is its
ability to assist in the treatment of chronic diseases that
can be periodically tracked using the specific clinical
variables. The interface of online informatics for pros-
tate cancer patients displays their PSA-related data asso-
ciated with statistical modules to provide categories of
Figure 5 A screen shot of real-time decision support that the clinician can use to evaluate the recurrence risk and the Partin table
online by flexibly adjusting clinical data.
Figure 6 A screen shot of interactive guideline that can highlight a suitable prostate cancer treatment flow based on a patient’s
clinical data.
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diagnostic information. Clinicians are able to identify
patients’ health conditions directly with respect to treat-
ments through the instant diagrams. The clinicians in
the study reported that the RTCDSS saved them hours,
even several days, of analysis by providing instant com-
putation of the relevant parameters. This study confirms
that the system can help clinicians quickly and accu-
rately identify treatment options, make the correct deci-
sion, and save time that was previously wasted.
B. Quality of treatment by system execution
The online guideline suggests the surgery treatment for
early-stage and younger patients as opposed to radio-
therapy for severe-stage or elder patients. If a patient’s
PSA is less than either 0.2 ng/ml or 2 ng/ml after the
surgery or radiotherapy, respectively, then the treatment
is counted as successful. In this study, 95 of prostate
cancer patients were selected for the pilot study because
their initial PSA data were recorded before the system
was installed. They were more easily convinced by evi-
dence-based diagrams with risk evaluation before
accepting the treatments. Correspondingly, 61 were sug-
gested for surgery and 34 for radiotherapy. They were
also tracked after treatments for various periods, 12
months at most. Table 2 shows the information of treat-
ments resulted in better control for patients who were
cured by either surgery or radiotherapy. In general, the
successful rates for both treatments reached more than
80%. Most of the patients’ PSA values improved after
the treatments, which confirms the treatment quality.
C. Improvement in the clinician-patients relationships
Several studies in chronic diseases suggest that feedback
of health status data may facilitate communication
between patients and clinicians and enhance patients’
care [38]. In this study, clinicians showed patients their
PSA-related trends via the charts, as shown in Figure 4
and explained to them the predicted potential disease
risk which was presented to them in a table, as shown
in Figure 5. Thus, the clinician could refer to the inter-
active guideline in Figure 6 while offering the sugges-
tions, ordering the proper treatment, and tracking the
follow-up conditions. The developed system enhances
clinicians’ awareness of their patients’ data with reliable
and predictive information related to prostate cancer
treatments through the real-time computation. Data
quality is hence ensured by the automatic transportation
procedure inherent in the system which minimizes man-
ual mistakes. It confirms the developed RTCDSS has the
capacity to improve clinician-patient relationships.
In the future, due to the flexibility and expandability
of the system, real-time data can be updated to incorpo-
rate developed decision support functions with predic-
tion models such as well-known nomograms, which
may help patients and their treating physicians make
informed decisions based on the probability of a patho-
logic stage, the individual patient’s risk tolerance, and
the values they place on the various potential outcomes
[39]. The system will aid the rational selection of
patients to undergo definitive therapy.
Conclusions
In this study we developed a novel real-time clinical
decision support system (RTCDSS) which was capable
of integrating data from numerous databases for practi-
cal use by clinicians to provide immediate visual feed-
back, facilitate decision-making, and to improve quality
of care. Such databases may include patients’ clinical
records, patient-reported outcomes, clinical variables,
and physicians’ practice guidelines. The proposed system
was applied for online clinical informatics of prostate
cancer as a pilot study. The system conferred the follow-
ing advantages: (1) clinicians could clearly explain health
conditions to patients by visualized clinical variables and
pretreatment parameters; (2) patients were more easily
convinced by evidence-based diagrams before accepting
the risk evaluation of treatments and the treatment
quality was confirmed; (3) the design presents a clini-
cian-oriented interface for real-time disease and risk
evaluation while the interactive guidelines with treat-
ment suggestions offer the clinician efficient online tools
for instant decision making; (4) the proposed framework
for prostate cancer treatment was constructed upon the
MVC-based architecture that consists of reusable
Table 2 Percentage improvements in patients’ PSA after surgery and radiotherapy treatments
months after treatment 1 3 6 9 12
Treatment (no. of successful treatments/patient number)
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models, making it flexible and adaptable for use in many
hospital information systems (HISs).
The results of this pilot study are related to prostate
cancer. However, the Web Model-View-Controller
(MVC) architecture can be readily applied in any trace-
able chronic disease, such as chronic pulmonary obstruc-
tive disease and asthma, as it allows for integration of a
wide range of relevant data in real-time to facilitate deci-
sion-making and improve quality of care.
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